List of Amturnide drug patents
Amturnide is owned by Novartis.
Amturnide contains Aliskiren Hemifumarate; Amlodipine Besylate; Hydrochlorothiazide.
Amturnide has a total of 1 drug patent out of which 0 drug patents have expired.
Amturnide was authorised for market use on 21 December, 2010.
Amturnide is available in tablet;oral dosage forms.
The generics of Amturnide are possible to be released after 16 May, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8183295 | NOVARTIS | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
May, 2023
(3 months from now) | |
Market Authorisation Date: 21 December, 2010
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic